Genmab Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Genmab AS
GMAB Stock  USD 20.80  0.29  1.41%   
Genmab AS financial statements provide useful quarterly and yearly information to potential Genmab AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Genmab AS financial statements helps investors assess Genmab AS's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Genmab AS's valuation are summarized below:
Gross Profit
20.5 B
Profit Margin
0.3644
Market Capitalization
13.1 B
Enterprise Value Revenue
3.242
Revenue
21.5 B
We have found one hundred twenty available fundamental trends for Genmab AS, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Genmab AS regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Genmab AS Total Revenue

22.6 Billion

Check Genmab AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.6 M, Interest Expense of 126 M or Selling General Administrative of 4 B, as well as many indicators such as Price To Sales Ratio of 4.23, Dividend Yield of 0.0 or PTB Ratio of 2.48. Genmab financial statements analysis is a perfect complement when working with Genmab AS Valuation or Volatility modules.
  
Check out the analysis of Genmab AS Correlation against competitors.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

Genmab AS Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets48.1 B45.8 B15.9 B
Slightly volatile
Other Current Liabilities3.7 B3.5 B964.4 M
Slightly volatile
Total Current Liabilities5.6 B5.3 B1.5 B
Slightly volatile
Total Stockholder Equity38.5 B36.7 B13.6 B
Slightly volatile
Property Plant And Equipment Net2 B1.9 B593.5 M
Slightly volatile
Cash10.4 B9.9 B4.3 B
Slightly volatile
Non Current Assets Total18.9 B18 B3.1 B
Slightly volatile
Non Currrent Assets Other1 B960 M151.1 M
Slightly volatile
Cash And Short Term Investments22.2 B21.1 B10.4 B
Slightly volatile
Common Stock Total Equity52.4 M75.9 M57.9 M
Slightly volatile
Common Stock Shares Outstanding61.4 M64.6 M321.5 M
Slightly volatile
Liabilities And Stockholders Equity48.1 B45.8 B15.9 B
Slightly volatile
Other Stockholder Equity7.8 B12.6 B8.6 B
Slightly volatile
Total Liabilities9.6 B9.1 B2.3 B
Slightly volatile
Property Plant And Equipment Gross2.9 B2.7 B796.9 M
Slightly volatile
Total Current Assets29.2 B27.9 B12.8 B
Slightly volatile
Intangible Assets13 B12.3 B1.7 B
Slightly volatile
Common Stock55.9 M75.9 M58.1 M
Slightly volatile
Short Term Investments11.8 B11.2 B6.1 B
Slightly volatile
Net Receivables6.9 B6.6 B2.3 B
Slightly volatile
Net Tangible Assets33 B31.4 B12 B
Slightly volatile
Other Assets243.7 M345 M168.3 M
Slightly volatile
Capital Surpluse9.5 B13.5 B9.4 B
Slightly volatile
Property Plant Equipment1.6 B1.5 B522.9 M
Slightly volatile
Net Invested Capital22.7 B36.7 B14.5 B
Slightly volatile
Net Working Capital19.8 B22.5 B12.8 B
Slightly volatile
Capital Stock71.7 M75.9 M64.4 M
Slightly volatile

Genmab AS Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization433.6 M413 M154 M
Slightly volatile
Interest Expense126 M120 M30.1 M
Slightly volatile
Selling General Administrative4 B3.8 B1.1 B
Slightly volatile
Other Operating Expenses15.6 B14.8 B4.3 B
Slightly volatile
Research Development10.2 B9.7 B3.1 B
Slightly volatile
Total Operating Expenses14.5 B13.8 B4.1 B
Slightly volatile
Total Revenue22.6 B21.5 B6.9 B
Slightly volatile
Interest Income1 B995 M270.7 M
Slightly volatile
Net Income From Continuing Ops8.2 B7.8 B2.5 B
Slightly volatile
Net Income Applicable To Common Shares6.7 B6.4 B2.6 B
Slightly volatile
Net Interest Income918.8 M875 M251.8 M
Slightly volatile
Reconciled Depreciation257.6 M413 M163.7 M
Slightly volatile

Genmab AS Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation433.6 M413 M155.1 M
Slightly volatile
Capital Expenditures124.7 M187 M163.2 M
Slightly volatile
End Period Cash Flow10.4 B9.9 B4.3 B
Slightly volatile
Stock Based Compensation757 M721 M218.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.234.450417.9631
Pretty Stable
PTB Ratio2.482.61057.9397
Slightly volatile
Days Sales Outstanding106112242
Slightly volatile
Book Value Per Share600572215
Slightly volatile
Stock Based Compensation To Revenue0.02340.03350.0284
Slightly volatile
Capex To Depreciation0.430.45281.7434
Pretty Stable
PB Ratio2.482.61057.9397
Slightly volatile
EV To Sales3.844.040217.2495
Pretty Stable
Inventory Turnover16.6815.88715.3451
Slightly volatile
Days Of Inventory On Hand21.8322.974693.7642
Slightly volatile
Payables Turnover0.110.0981.1139
Slightly volatile
Sales General And Administrative To Revenue0.07140.07520.1379
Slightly volatile
Research And Ddevelopement To Revenue0.430.45280.83
Slightly volatile
Capex To Revenue0.00830.00870.0521
Slightly volatile
Cash Per Share345329164
Slightly volatile
Days Payables Outstanding3.5 K3.4 K3.3 K
Slightly volatile
Intangibles To Total Assets0.340.32480.0597
Slightly volatile
Current Ratio7.265.24769.9821
Slightly volatile
Tangible Book Value Per Share357340183
Slightly volatile
Receivables Turnover4.313.26653.6381
Pretty Stable
Graham Number1.3 K1.3 K444
Slightly volatile
Shareholders Equity Per Share600572215
Slightly volatile
Debt To Equity0.02260.0280.0148
Slightly volatile
Capex Per Share1.582.91342.7469
Slightly volatile
Graham Net Net277264153
Slightly volatile
Revenue Per Share352335108
Slightly volatile
Interest Debt Per Share18.817.90094.991
Slightly volatile
Debt To Assets0.02360.02250.0118
Slightly volatile
Short Term Coverage Ratios1.382.082.1697
Very volatile
Operating Cycle262135259
Slightly volatile
Price Book Value Ratio2.482.61057.9397
Slightly volatile
Days Of Payables Outstanding3.5 K3.4 K3.3 K
Slightly volatile
Ebt Per Ebit0.731.36711.0031
Slightly volatile
Company Equity Multiplier1.681.24841.5972
Slightly volatile
Total Debt To Capitalization0.02150.02730.0145
Slightly volatile
Debt Equity Ratio0.02260.0280.0148
Slightly volatile
Quick Ratio7.265.23599.9985
Slightly volatile
Net Income Per E B T1.070.8560.9299
Slightly volatile
Cash Ratio1.881.85722.5657
Slightly volatile
Days Of Inventory Outstanding21.8322.974693.7642
Slightly volatile
Days Of Sales Outstanding106112242
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.020.97590.8929
Very volatile
Price To Book Ratio2.482.61057.9397
Slightly volatile
Fixed Asset Turnover12.6211.383419.2892
Pretty Stable
Debt Ratio0.02360.02250.0118
Slightly volatile
Price Sales Ratio4.234.450417.9631
Pretty Stable
Asset Turnover0.490.46990.3554
Slightly volatile
Price Fair Value2.482.61057.9397
Slightly volatile

Genmab AS Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap88.1 B84 B80.9 B
Slightly volatile
Enterprise Value85 B80.9 B78 B
Slightly volatile

Genmab Fundamental Market Drivers

Forward Price Earnings11.7925
Cash And Short Term Investments21.1 B

Genmab Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Genmab AS Financial Statements

Genmab AS stakeholders use historical fundamental indicators, such as Genmab AS's revenue or net income, to determine how well the company is positioned to perform in the future. Although Genmab AS investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab AS's assets and liabilities are reflected in the revenues and expenses on Genmab AS's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue24 M22.8 M
Total Revenue21.5 B22.6 B
Cost Of Revenue985 M1 B
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.08  0.07 
Research And Ddevelopement To Revenue 0.45  0.43 
Capex To Revenue 0.01  0.01 
Revenue Per Share 335.37  352.13 
Ebit Per Revenue 0.31  0.30 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
How To Invest In Genmab
Details
Is Genmab Stock a good investment?
Details
What is Genmab AS's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Genmab AS Correlation against competitors.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.634
Earnings Share
1.77
Revenue Per Share
33.5366
Quarterly Revenue Growth
0.353
Return On Assets
0.1091
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY